In an exploratory analysis of 78 patients with CP B7–8 at baseline, there was no difference in median OS between the treatment arms (HR 1.00, 95% CI 0.62, 1.60; p ≥ 0.99) and there was a higher incidence of Grade 3 or 4 toxicity than in patients with CP A.62Stratification of median OS by ALBI in the REFLECT, RESORCE, CELESTIAL, and REACH trials showed that MKIs and ramucirumab were no better than sorafenib in patients with advanced HCC and moderate liver dysfunction. Here, CP is linked to hepatocellular carcinoma.